LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Part of paid clinical trials in Bridgewater, New Jersey.

Sponsor
Bausch Health Americas, Inc.
Study ID
NCT03254667
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Brodalumab — BIOLOGICAL
    Brodalumab
  • Comparator Drug (non-biologic IL-17 inhibitors) — DRUG
    Comparator subjects treated with non-biologic IL-17 inhibitors

Study Details

Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis

Key Dates

Start date
Jul 25, 2017
Status verified
Sep 2025
Primary completion
Nov 10, 2030
Completion
Nov 30, 2031

Study Design

Enrollment
3,500 participants (estimated)

Arms

  • Arm: Brodalumad exposed
    1500 subjects exposes to brodalumab
  • Arm: Comparator Subjects
    2000 comparator subjects

Primary Outcome Measure

Assess the incidence of malignancy [ Time Frame: 8 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
RegistryBridgewaterNew Jersey08807-

Find similar trials in Bridgewater, NJ

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Registry· Bridgewater, NJ

Related Studies